EMA/426558/2011

European Medicines Agency decision

P/128/2011

of 8 June 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral for ipilimumab (EMEA-000117-PIP02-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/128/2011

of 8 June 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral for ipilimumab (EMEA-000117-PIP02-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Bristol-Myers Squibb International Corporation on 7 June 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 April 2011, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ipilimumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ipilimumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Bristol-Myers Squibb International Corporation, Parc de l'Alliance, Avenue de Finlande 8, 1420 - Braine-l'Alleud, Belgium.

Done at London, 8 June 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)

EMA/PDCO/204826/2011

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-000117-PIP02-10

Scope of the application

Active substance(s):

Ipilimumab

Condition(s):

Treatment of melanoma

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb International Corporation

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb International Corporation submitted for agreement to the European Medicines Agency on 7 June 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 15 July 2010.

Supplementary information was provided by the applicant on 4 February 2011. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 20 April 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of melanoma

2.1.1. Indication(s) targeted by the PIP

Treatment of pre-treated and naive patients with advanced metastatic melanoma.

Treatment of patients with melanoma surgically resected in the adjuvant setting.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	1	Study 1 Intravenous study of pre- and postnatal development in cynomolgus monkeys with a 6-month postnatal evaluation.
Clinical	3	Study 2 Open-label, dose escalation clinical trial of intravenously administered ipilimumab in children from 3 to less than 18 years (and adults) with untreatable, refractory or relapsed solid malignant tumours to evaluate pharmacokinetics and safety. Study 3 Open-label, multi-center, single-arm clinical trial of intravenously administered ipilimumab in children aged 12 to less than 18 years with untreated or previously treated advanced/metastatic melanoma to evaluate efficacy and safety. Study 4 Open-label randomized active-controlled study of adjuvant ipilimumab anti-CTLA4 therapy versus high-dose interferon α-2b in children aged 12 to less than 18 years (and adults) with resected high-risk melanoma to evaluate

Area	Number of studies	Description
		efficacy, safety and tolerability.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2017
Deferral for one or more studies contained in the paediatric investigation plan:	Yes